FLT3 Mutation Analysis
Alternative name:
FLT3, FLT3 ITD
Methodology
Molecular
Test Description and clinical significance
Genes
FLT3 (ITD variants , exon14,15)
Disease:
Acute myeloid leukemia (AML), colon adenocarcinoma, lung adenocarcinoma, cutaneous melanoma, and breast invasive ductal carcinoma
A polymerase chain reaction test aiming for detection of mutations in the FLT3 gene which are common mutations in acute myeloid leukemia (AML). This assay detects internal tandem duplication (ITD) mutations and mutations in the tyrosine kinase domain (TKD) of FLT3. Presence of these mutations in AML provide prognostic information and can aid in the determination of therapeutic regimen.
NGS-AML Panel is recommended.
Specimen Requirements
Collection:
at least 0.5 mL EDTA, citrate (ACD) or Heparinized bone marrow and peripheral blood specimens
Stability:
96hours/4 to 7 days refrigerated
Unacceptable Conditions:
Specimen submitted is in the incorrect fixative or anticoagulant. Specimen received after the stability date. Gross hemolysis. Frozen specimen. Insufficient specimen. Unlabeled
Storage & Transport
Blood or bone marrow specimens should be kept at room temperature and preferably received within 96 hours of drawing. Samples that are 4 to 7 days old should be refrigerated.
CPT(s)
81245
New York Approved
NO
TAT
5 Days
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
